{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,11]],"date-time":"2026-03-11T17:53:24Z","timestamp":1773251604837,"version":"3.50.1"},"reference-count":40,"publisher":"Public Library of Science (PLoS)","issue":"12","license":[{"start":{"date-parts":[[2022,12,15]],"date-time":"2022-12-15T00:00:00Z","timestamp":1671062400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004731","name":"Natural Science Foundation of Zhejiang Province","doi-asserted-by":"publisher","award":["LQ19H280001"],"award-info":[{"award-number":["LQ19H280001"]}],"id":[{"id":"10.13039\/501100004731","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100017594","name":"Medical Science and Technology Project of Zhejiang Province","doi-asserted-by":"publisher","award":["2019KY037"],"award-info":[{"award-number":["2019KY037"]}],"id":[{"id":"10.13039\/501100017594","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100017594","name":"Medical Science and Technology Project of Zhejiang Province","doi-asserted-by":"publisher","award":["2022KY090"],"award-info":[{"award-number":["2022KY090"]}],"id":[{"id":"10.13039\/501100017594","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Project of Clinical Comprehensive Pharmaceutical Evaluation of Zhejiang Pharmaceutical Association","award":["2022ZYYL20"],"award-info":[{"award-number":["2022ZYYL20"]}]},{"name":"Special Research Program of Pharmacoeconomics and Health Technology Assessment Committee of Zhejiang Pharmaceutical Association","award":["2022ZYJ10"],"award-info":[{"award-number":["2022ZYJ10"]}]},{"name":"Special Research Program of Pharmacoeconomics and Health Technology Assessment Committee of Zhejiang Pharmaceutical Association","award":["2022ZYJ18"],"award-info":[{"award-number":["2022ZYJ18"]}]}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"abstract":"<jats:sec id=\"sec001\">\n<jats:title>Objectives<\/jats:title>\n<jats:p>Poly (ADP-ribose) polymerase inhibitor (PARPi) have become a mainstay for the treatment of BRCA-mutant malignancies. PARPis are likely to be more effective but also bring an increase in costs. Thus, we aimed at evaluating the cost effectiveness of PARPis in the treatment of malignancies.<\/jats:p>\n<\/jats:sec>\n<jats:sec id=\"sec002\">\n<jats:title>Methods<\/jats:title>\n<jats:p>Studies of cost effectiveness of PARPis were searched from PubMed, Web of Science, and Cochrane Library. Key information was extracted from the identified studies and reviewed. Quality of the included studies was evaluated using Quality of Health Economic Studies (QHES) instrument. Modeling techniques, measurement of parameters and uncertainty analysis were analyzed across studies. Interventions and cost-effectiveness results were reported stratified by patient population.<\/jats:p>\n<\/jats:sec>\n<jats:sec id=\"sec003\">\n<jats:title>Results<\/jats:title>\n<jats:p>Among the 25 studies identified, we included 17 on ovarian cancer, 2 on breast cancer, 3 on pancreatic cancer, and 3 on prostate cancer that involved olaparib, niraparib, rucaparib, and talazoparib. All studies had a QHES score of above 75. In the maintenance therapy of ovarian cancer, additional administration of olaparib was cost-effective for newly diagnosed patients after first-line platinum-based chemotherapy but was not cost-effective for platinum-sensitive recurrent patients in majority studies. However, the economic value of other PARPis in ovarian cancer as well as all PARPis in other tumors remained controversial. Cost-effectiveness of PARPi was primarily impacted by the costs of PARPi, survival time, health utility and discount rate. Moreover, genetic testing improved the cost-effectiveness of PARPi treatment.<\/jats:p>\n<\/jats:sec>\n<jats:sec id=\"sec004\">\n<jats:title>Conclusions<\/jats:title>\n<jats:p>PARPi is potentially cost-effective for patients with ovarian, pancreatic, or prostate cancer. Genetic testing can improve the cost-effectiveness of PARPi.<\/jats:p>\n<\/jats:sec>","DOI":"10.1371\/journal.pone.0279286","type":"journal-article","created":{"date-parts":[[2022,12,15]],"date-time":"2022-12-15T18:55:56Z","timestamp":1671130556000},"page":"e0279286","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":4,"title":["Cost-effectiveness of PARP inhibitors in malignancies: A systematic review"],"prefix":"10.1371","volume":"17","author":[{"given":"Haiying","family":"Ding","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chaoneng","family":"He","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yinghui","family":"Tong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qilu","family":"Fang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiufang","family":"Mi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lingya","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wenxiu","family":"Xin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8070-5662","authenticated-orcid":true,"given":"Luo","family":"Fang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"340","published-online":{"date-parts":[[2022,12,15]]},"reference":[{"issue":"12","key":"pone.0279286.ref001","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1038\/nrd3868","article-title":"Tankyrase-targeted therapeutics: expanding opportunities in the PARP family.","volume":"11","author":"JL Riffell","year":"2012","journal-title":"Nat Rev Drug Discov"},{"issue":"7826","key":"pone.0279286.ref002","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1038\/s41586-020-2725-7","article-title":"Bridging of DNA breaks activates PARP2-HPF1 to modify chromatin","volume":"585","author":"S Bilokapic","year":"2020","journal-title":"Nature"},{"issue":"6330","key":"pone.0279286.ref003","doi-asserted-by":"crossref","first-page":"1152","DOI":"10.1126\/science.aam7344","article-title":"PARP inhibitors: Synthetic lethality in the clinic","volume":"355","author":"CJ Lord","year":"2017","journal-title":"Science"},{"issue":"1","key":"pone.0279286.ref004","doi-asserted-by":"crossref","first-page":"e15","DOI":"10.1016\/S1470-2045(18)30786-1","article-title":"Exploring and comparing adverse events between PARP inhibitors","volume":"20","author":"CJ LaFargue","year":"2019","journal-title":"Lancet Oncol"},{"issue":"10106","key":"pone.0279286.ref005","doi-asserted-by":"crossref","first-page":"1949","DOI":"10.1016\/S0140-6736(17)32440-6","article-title":"Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomised, double-blind, placebo-controlled, phase 3 trial.","volume":"390","author":"RL Coleman","year":"2017","journal-title":"Lancet"},{"issue":"5","key":"pone.0279286.ref006","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1016\/S1470-2045(19)30029-4","article-title":"Niraparib monotherapy for late-line treatment of ovarian cancer (QUADRA): a multicentre, open-label, single-arm, phase 2 trial.","volume":"20","author":"KN Moore","year":"2019","journal-title":"Lancet Oncol."},{"issue":"13","key":"pone.0279286.ref007","doi-asserted-by":"crossref","first-page":"1302","DOI":"10.1200\/JCO.2013.51.4489","article-title":"Bevacizumab combined with chemotherapy for platinum-resistant recurrent ovarian cancer: The AURELIA open-label randomized phase III trial","volume":"32","author":"E Pujade-Lauraine","year":"2014","journal-title":"J Clin Oncol"},{"issue":"9","key":"pone.0279286.ref008","doi-asserted-by":"crossref","first-page":"1274","DOI":"10.1016\/S1470-2045(17)30469-2","article-title":"Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1\/2 mutation (SOLO2\/ENGOT-Ov21): a double-blind, randomised, placebo-controlled, phase 3 trial.","volume":"18","author":"E Pujade-Lauraine","year":"2017","journal-title":"Lancet Oncol."},{"issue":"22","key":"pone.0279286.ref009","doi-asserted-by":"crossref","first-page":"2091","DOI":"10.1056\/NEJMoa1911440","article-title":"Olaparib for Metastatic Castration-Resistant Prostate Cancer","volume":"382","author":"J de Bono","year":"2020","journal-title":"N Engl J Med"},{"issue":"4","key":"pone.0279286.ref010","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1056\/NEJMoa1903387","article-title":"Maintenance Olaparib for Germline BRCA-Mutated Metastatic Pancreatic Cancer","volume":"381","author":"T Golan","year":"2019","journal-title":"N Engl J Med"},{"issue":"25","key":"pone.0279286.ref011","doi-asserted-by":"crossref","first-page":"2391","DOI":"10.1056\/NEJMoa1910962","article-title":"Niraparib in Patients with Newly Diagnosed Advanced Ovarian Cancer","volume":"381","author":"A Gonz\u00e1lez-Mart\u00edn","year":"2019","journal-title":"N Engl J Med"},{"issue":"8","key":"pone.0279286.ref012","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1056\/NEJMoa1802905","article-title":"Talazoparib in Patients with Advanced Breast Cancer and a Germline BRCA Mutation","volume":"379","author":"JK Litton","year":"2018","journal-title":"N Engl J Med"},{"issue":"11","key":"pone.0279286.ref013","doi-asserted-by":"crossref","first-page":"1201","DOI":"10.1007\/s40273-020-00949-9","article-title":"A Critical Appraisal and Recommendations for Cost-Effectiveness Studies of Poly(ADP-Ribose) Polymerase Inhibitors in Advanced Ovarian Cancer.","volume":"38","author":"W Gao","year":"2020","journal-title":"Pharmacoeconomics"},{"issue":"5","key":"pone.0279286.ref014","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1016\/j.ijsu.2010.02.007","article-title":"Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement.","volume":"8","author":"D Moher","year":"2010","journal-title":"Int J Surg"},{"issue":"2","key":"pone.0279286.ref015","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1053\/j.gastro.2004.04.020","article-title":"The quality of published health economic analyses in digestive diseases: a systematic review and quantitative appraisal","volume":"127","author":"BM Spiegel","year":"2004","journal-title":"Gastroenterology"},{"issue":"5","key":"pone.0279286.ref016","first-page":"846","article-title":"Cost-effectiveness of BRCA1 and BRCA2 mutation testing to target PARP inhibitor use in platinum-sensitive recurrent ovarian cancer","volume":"23","author":"AA Secord","year":"2013","journal-title":"Int J Gynecol Cancer"},{"issue":"1","key":"pone.0279286.ref017","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/j.ygyno.2015.08.013","article-title":"PARP inhibitor maintenance therapy for patients with platinum-sensitive recurrent ovarian cancer: a cost-effectiveness analysis","volume":"139","author":"HJ Smith","year":"2015","journal-title":"Gynecol Oncol"},{"issue":"12","key":"pone.0279286.ref018","first-page":"1219","article-title":"Cost-Effectiveness of Niraparib and Olaparib as Maintenance Therapy for Patients with Platinum-Sensitive Recurrent Ovarian Cancer.","volume":"24","author":"L Zhong","year":"2018","journal-title":"J Manag Care Spec Pharm"},{"issue":"4","key":"pone.0279286.ref019","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1097\/AOG.0000000000003171","article-title":"U.S. Food and Drug Administration-Approved Poly (ADP-Ribose) Polymerase Inhibitor Maintenance Therapy for Recurrent Ovarian Cancer: A Cost-Effectiveness Analysis.","volume":"133","author":"JA Dottino","year":"2019","journal-title":"Obstet Gynecol"},{"issue":"3","key":"pone.0279286.ref020","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1007\/s40273-018-0745-z","article-title":"Cost-Effectiveness of Niraparib Versus Routine Surveillance, Olaparib and Rucaparib for the Maintenance Treatment of Patients with Ovarian Cancer in the United States.","volume":"37","author":"H Guy","year":"2019","journal-title":"Pharmacoeconomics"},{"issue":"6","key":"pone.0279286.ref021","doi-asserted-by":"crossref","first-page":"439","DOI":"10.2217\/pme-2018-0141","article-title":"Cost-effectiveness of BRCA1\/2 mutation profiling to target olaparib use in patients with metastatic breast cancer","volume":"16","author":"S Saito","year":"2019","journal-title":"Per Med"},{"issue":"7","key":"pone.0279286.ref022","doi-asserted-by":"crossref","first-page":"1192","DOI":"10.1016\/j.clinthera.2020.04.015","article-title":"Cost-Effectiveness and Net Monetary Benefit of Olaparib Maintenance Therapy Versus No Maintenance Therapy After First-line Platinum-based Chemotherapy in Newly Diagnosed Advanced BRCA1\/2-mutated Ovarian Cancer in the Italian National Health Service","volume":"42","author":"P Armeni","year":"2020","journal-title":"Clin Ther"},{"issue":"10","key":"pone.0279286.ref023","doi-asserted-by":"crossref","first-page":"1569","DOI":"10.1136\/ijgc-2020-001550","article-title":"Niraparib maintenance in frontline management of ovarian cancer: a cost effectiveness analysis","volume":"30","author":"DA Barrington","year":"2020","journal-title":"Int J Gynecol Cancer"},{"issue":"2","key":"pone.0279286.ref024","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1016\/j.ygyno.2020.08.003","article-title":"Cost-effectiveness analysis comparing \"PARP inhibitors-for-all\" to the biomarker-directed use of PARP inhibitor maintenance therapy for newly diagnosed advanced stage ovarian cancer.","volume":"159","author":"R Gonzalez","year":"2020","journal-title":"Gynecol Oncol"},{"issue":"2","key":"pone.0279286.ref025","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1016\/j.ygyno.2020.08.013","article-title":"Cost-effectiveness of olaparib as a maintenance treatment for women with newly diagnosed advanced ovarian cancer and BRCA1\/2 mutations in the United States","volume":"159","author":"D Muston","year":"2020","journal-title":"Gynecol Oncol"},{"issue":"12","key":"pone.0279286.ref026","doi-asserted-by":"crossref","first-page":"e2028620","DOI":"10.1001\/jamanetworkopen.2020.28620","article-title":"Cost-effectiveness of Maintenance Therapy Based on Molecular Classification Following Treatment of Primary Epithelial Ovarian Cancer in the United States.","volume":"3","author":"CA Penn","year":"2020","journal-title":"JAMA Netw Open"},{"key":"pone.0279286.ref027","doi-asserted-by":"crossref","first-page":"610601","DOI":"10.3389\/fphar.2020.610601","article-title":"Cost-Effectiveness of Genomic Test-Directed Olaparib for Metastatic Castration-Resistant Prostate Cancer.","volume":"11","author":"D Su","year":"2020","journal-title":"Front Pharmacol"},{"issue":"2","key":"pone.0279286.ref028","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1016\/j.ygyno.2020.02.030","article-title":"Cost-effectiveness of niraparib, rucaparib, and olaparib for treatment of platinum-resistant, recurrent ovarian carcinoma","volume":"157","author":"JE Wolford","year":"2020","journal-title":"Gynecol Oncol"},{"issue":"11","key":"pone.0279286.ref029","doi-asserted-by":"crossref","first-page":"1528","DOI":"10.6004\/jnccn.2020.7587","article-title":"Cost-Effectiveness of Maintenance Olaparib for Germline BRCA-Mutated Metastatic Pancreatic Cancer.","volume":"18","author":"B Wu","year":"2020","journal-title":"J Natl Compr Canc Netw"},{"key":"pone.0279286.ref030","doi-asserted-by":"crossref","first-page":"12919","DOI":"10.2147\/CMAR.S283169","article-title":"Cost-Effectiveness Analysis of Maintenance Olaparib in Patients with Metastatic Pancreatic Cancer and a Germline BRCA1\/2 Mutation Based on the POLO Trial.","volume":"12","author":"M Zhan","year":"2020","journal-title":"Cancer Manag Res."},{"key":"pone.0279286.ref031","first-page":"1","article-title":"Cost-effectiveness of olaparib maintenance therapy when used with and without restriction by BRCA1\/2 mutation status for platinum-sensitive relapsed ovarian cancer","author":"LJ Cheng","year":"2021","journal-title":"Expert Rev Pharmacoecon Outcomes Res"},{"key":"pone.0279286.ref032","doi-asserted-by":"crossref","first-page":"632818","DOI":"10.3389\/fphar.2021.632818","article-title":"Cost-Effectiveness Analysis of Olaparib Maintenance Treatment for Germline BRCA-Mutated Metastatic Pancreatic Cancer.","volume":"12","author":"N Li","year":"2021","journal-title":"Front Pharmacol"},{"key":"pone.0279286.ref033","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.breast.2021.04.004","article-title":"Cost-utility of talazoparib monotherapy treatment for locally advanced or metastatic breast cancer in Spain.","volume":"58","author":"A Olry de Labry Lima","year":"2021","journal-title":"Breast"},{"issue":"2","key":"pone.0279286.ref034","doi-asserted-by":"crossref","first-page":"e27","DOI":"10.3802\/jgo.2021.32.e27","article-title":"Cost-effectiveness of olaparib versus routine surveillance in the maintenance setting for patients with BRCA-mutated advanced ovarian cancer after response to first-line platinum-based chemotherapy in Singapore.","volume":"32","author":"DS Tan","year":"2021","journal-title":"J Gynecol Oncol"},{"key":"pone.0279286.ref035","first-page":"1","article-title":"Cost-effectiveness analysis of olaparib and niraparib as maintenance therapy for women with recurrent platinum-sensitive ovarian cancer","author":"JH Leung","year":"2021","journal-title":"Expert Rev Pharmacoecon Outcomes Res"},{"issue":"13","key":"pone.0279286.ref036","doi-asserted-by":"crossref","first-page":"809","DOI":"10.2217\/pgs-2021-0061","article-title":"Is olaparib cost effective in metastatic castration-resistant prostate cancer patients with at least one favorable gene mutation in BRCA1, BRCA2 or ATM","volume":"22","author":"Y Li","year":"2021","journal-title":"Pharmacogenomics"},{"issue":"2","key":"pone.0279286.ref037","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1016\/j.ygyno.2021.11.011","article-title":"Olaparib as first line in BRCA-mutated advanced ovarian carcinoma: Is it cost-effective in Spain?","volume":"164","author":"C Moya-Alarc\u00f3n","year":"2022","journal-title":"Gynecol Oncol"},{"key":"pone.0279286.ref038","article-title":"Cost-Effectiveness Analysis of Olaparib in Combination with Bevacizumab Compared with Bevacizumab Monotherapy for the First-Line Maintenance Treatment of Homologous Recombination Deficiency-Positive Advanced Ovarian Cancer","author":"D Elsea","year":"2022","journal-title":"Pharmacoecon Open"},{"key":"pone.0279286.ref039","doi-asserted-by":"crossref","first-page":"818579","DOI":"10.3389\/fphar.2022.818579","article-title":"Cost-effectiveness analysis of olaparib as maintenance therapy in patients with platinum-sensitive relapsed ovarian cancer and a BRCA1\/2 mutation in china.","volume":"13","author":"Y Shu","year":"2022","journal-title":"Front Pharmacol."},{"issue":"15","key":"pone.0279286.ref040","doi-asserted-by":"crossref","first-page":"830","DOI":"10.21037\/atm-22-3637","article-title":"Cost-effectiveness of olaparib, a PARP inhibitor, for patients with metastatic castration-resistant prostate cancer in China and United States.","volume":"10","author":"C Xu","year":"2022","journal-title":"Ann Transl Med"}],"container-title":["PLOS ONE"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0279286","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,15]],"date-time":"2022-12-15T18:56:24Z","timestamp":1671130584000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0279286"}},"subtitle":[],"editor":[{"given":"Giurato","family":"Giorgio","sequence":"first","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]}],"short-title":[],"issued":{"date-parts":[[2022,12,15]]},"references-count":40,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2022,12,15]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0279286","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,12,15]]}}}